Eli Lilly and Company
As of Fiscal Year 2025 (ended December 31, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total revenue (FY2025) | $65.18 billion, up 45% year-over-year |
| GAAP net income (FY2025) | $20.64 billion, up 95% year-over-year |
| GAAP diluted EPS (FY2025) | $22.95, up 96% year-over-year |
| Gross margin (FY2025) | 83.0% of revenue, up from 81.3% in FY2024 |
| R&D expense (FY2025) | $13.34 billion, 20.5% of revenue |
| Combined Mounjaro + Zepbound revenue (FY2025) | $36.51 billion, more than double FY2024's $16.47 billion |
| U.S. GLP-1/incretin market share | More than 60%, per Lilly's own statement on its Q4 2025 earnings call (reported by BioPharma Dive, February 2026) |
| Employees worldwide | Approximately 51,168 (as of June 30, 2026, per Lilly's Key Facts page) |
Sources: Figures are from Eli Lilly's Q4/full-year 2025 earnings release (issued February 4, 2026) and its 'Key Facts' investor page. Lilly discloses individual full-year revenue only for its three largest branded products (Mounjaro, Zepbound, Verzenio); the 'All Other Products' pie slice is a derived residual (total revenue minus those three named products), not a single disclosed line item, and includes the rest of Lilly's diabetes, oncology, immunology and other portfolio (e.g. Trulicity, Jardiance, Taltz, Verzenio, Omvoh, Ebglyss, Kisunla, Jaypirca, and legacy products). The GLP-1/obesity market-share figure is Lilly's own claim, reported via BioPharma Dive's coverage of the Q4 2025 earnings call, not an independent third-party estimate.